导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.05% | 3059/4773 |
| 近一周 | -1.97% | 985/5462 |
| 近一月 | -2.82% | 1418/5421 |
| 近一季 | -4.21% | 1559/5209 |
| 近半年 | -4.61% | 2558/4920 |
| 近一年 | -1.50% | 2880/4366 |
| 近两年 | 39.23% | 1926/2954 |
| 近三年 | 25.70% | 1248/2253 |
| 成立以来 | 95.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.07% 3511/4961 |
7.42% 2702/5312 |
- - |
- - |
| 2025 | 17.74% 2357/4813 |
-1.29% 2627/3635 |
2.79% 1347/4076 |
16.84% 2595/4524 |
-0.69% 2598/4813 |
| 2024 | 18.31% 611/3463 |
3.85% 506/2808 |
-0.38% 756/3014 |
15.21% 1784/3129 |
-0.73% 1510/3463 |
| 2023 | -7.00% 887/2656 |
3.13% 1255/2280 |
-3.28% 763/2385 |
-0.16% 404/2515 |
-6.62% 1850/2655 |
| 2022 | -15.90% 436/2207 |
-10.89% 450/1919 |
5.66% 847/2016 |
-12.19% 664/2113 |
1.72% 1167/2208 |
| 2021 | -3.40% 904/1822 |
-2.45% 644/1255 |
1.93% 1030/1330 |
-4.11% 682/1466 |
1.31% 968/1822 |
| 2020 | 20.80% 704/1250 |
-10.53% 789/1028 |
9.57% 788/1067 |
10.58% 535/1164 |
11.44% 540/1184 |
| 2019 | 30.66% 479/1092 |
23.22% 560/754 |
1.78% 111/804 |
-0.89% 623/850 |
5.12% 747/918 |
| 2018 | -18.91% 153/834 |
- - |
- - |
- - |
-10.98% 238/691 |
| 2017 | 20.04% 188/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.44% 217/605 |
- - |
- - |
- - |
- - |
| 2015 | 3.68% 232/575 |
- - |
- - |
- - |
- - |
| 2014 | 58.86% 40/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.58% 116/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.47% 32/140 |
- - |
- - |
- - |
- - |
| 2011 | -21.96% 47/102 |
- - |
- - |
- - |
- - |
| 2010 | -14.43% 38/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安上证180ETF联接A VS. 长安沪深300非周期A(740101) |